May 17, 2020

The six most expensive medical procedures as of 2015

Patient Care
Hospital Finance
United States
4 min
Involving both the largest and the longest organ within the body, an intestinal transplant is a last resort procedure that is only performed on patients with life threatening conditions.
Health care in the United States is expensive, but which medical procedures carry the costliest price tags?

In the August issue of Healthcare Global ma...

Health care in the United States is expensive, but which medical procedures carry the costliest price tags?

In the August issue of Healthcare Global magazine, we profiled the top 10 most expensive medical procedures, below are the top six. For the complete list, read the article here.

Click here to read the September 2015 edition of Healthcare Global magazine!

6. Liver transplant — USD$577,100

An extremely vital organ that aids in the digestion, blood clotting and a host of other essential functions, the liver is integral to the entire body. Thus, the risks associated with a liver transplant are very high, even more life threatening than many other serious medical procedures. 

Once becoming eligible for the transplant and the difficult process of finding a donor is achieved, costs build in the form of extensive recovery time and post-op as well as medications and recurring appointments with a specialist.

5. Bone marrow transplant — USD$676,800

A bone marrow transplant is a varied type of medical procedure that can be performed in two different ways. An autologous bone marrow transplant is when stem cells are removed from the body and frozen. After treatment for the condition afflicting the patient (generally cancer) is finished, the cells are put back into the body to regenerate healthy blood cells. This procedure costs around USD$300,000.

RELATED TOPIC: Doctors want more Ebola cases, here's why

The second, more expensive bone marrow transplant, involves finding a donor. This type of transplant, called an allogenic transplant, can cost up to USD$676,800 due to the time and effort put into finding and researching a donor who is a match, as well as the medical procedure itself.

4. Lung transplant — USD$797,200 double, USD$561,200 single

Lung transplants are used for people who are likely to die from lung disease within one to two years. Their conditions are so severe that other treatments, such as medicines or breathing devices, no longer work. There are a myriad of factors that make the procedure so expensive; first, finding a donor, then the surgery itself, where the patient is placed on a machine to breathe.

RELATED TOPIC: How surgical hospitals can expand in 2016 via technology

Afterwards patients recover in the intensive care unit for a few days, before spending another three weeks in hospital. All in all, the procedure, hospital recovery time and subsequent rehab that may take over three months, plus the medications needed to avoid transplant rejection contribute to the procedure’s high cost.

3. Heart transplant — USD$997,000

The most common method of performing a heart transplant is to remove the patient’s dying heart after having harvested a still living heart from a recently deceased donor and graft it into the patient’s body. A heart transplant is by no means a cure for those patients in the end stages of heart disease, but merely a method of prolonging the length and quality of one’s life.

In reality, the life expectancy for the recipient of a heart transplant is 15 years after the procedure, and some of the time post-op is extremely difficult. Recovery in intensive care is followed by a lengthy rehabilitation period with plenty of hospital visits with specialists to ensure the health of the patient. Beyond rehabilitation, recipients of a heart transplant also run the high risk of infection and organ rejection, hence the immunosuppressant drugs prescribed to limit the risk.

2. Heart-lung transplant — USD$1,148,400

A combined heart and lung transplant is extremely rare in the United States, with roughly 100 performed annually. The difficulty in finding a donor is a primary reason, beyond the difficulty in the operation itself. Candidates must be under the age of 55 and be healthy enough otherwise to survive the rehabilitation period and regimen of immunosuppressant drugs to prevent infection and rejection.

During surgery both the dying heart and lungs are removed and the patient is connected to a machine that will facilitate breathing and the circulation of blood to the body. While still incredibly rare and risky, and exorbitantly expensive at a cost of over a million dollars, survival rates for heart-lung transplant patients has increased to nearly 85 percent a year after surgery.

1. Intestine transplant — USD$1,206,000

Although it is possible for a living donor to donate an intestine segment, most intestine transplants involve a whole organ from a deceased donor. In addition, most intestine transplants are performed in conjunction with a liver transplant. Involving both the largest and the longest organ within the body, an intestinal transplant is again another last resort procedure that is only performed on patients with life threatening conditions, leaving no other option.

RELATED TOPIC: TOP 10: Best hospitals to work for in the Northeast USA

A complex procedure that requires a highly skilled transplant team, the entire surgery can last anywhere from four to 12 hours. In some cases patients will receive both liver and intestine transplants concurrently, making this medical procedure the most complex, time consuming and expensive medical procedure in the United States.

Let's connect!   

Share article

Jun 10, 2021

The future of pharma: personalised healthcare

6 min
Chris Easton, Global Commercial Lead at Takeda, tells us how the pharmaceutical sector can help deliver more personalised care

Ever since the very first healthcare systems were created, the earliest documented being in ancient Egypt, medical professionals have had a reactionary approach   to finding cures for ailments. That is to say that a solution is sought after someone has become sick, using whatever methods were thought to work at the time. Thousands of years later, with advances in genomics and molecular modelling, emphasis is starting to shift towards preventative, personalised healthcare rather than "sick care". 

This move is led by data analytics as well as genetic sequencing to inform decision-making, which can ultimately lead to more individualised care. "Identifying the right data will support personalised health outcomes", explains Chris Easton, who is Takeda’s Senior Director and Global Commercial Lead, specialising in personalised health and innovation and applying this to rare blood disorders. "It's about how we can empower patients, interpret data and then apply it."

"The historic pharma model, in a very simplified form, is: a patient has symptoms, gets diagnosed, and gets given drugs for symptoms", Easton says. "Now, with holistic patient care in mind, it's much more about the additional components to care that would make a difference. Yes, drug therapy is one of them, but likewise, it's okay to talk about mental health, as the impact of chronic diseases means often there is a mental health challenge. So what can we do to build a mental health and physical health support package, both of which have data associated with them, that we can use together?"

By way of example, Easton cites the approach taken by elite athletes and astronauts. "Their model is to keep as healthy as possible. If someone on a space mission gets a cold, they're off the mission - it's not affordable to send someone to space that might have a health issue. If you look at footballers and runners, their coaches maintain them at the highest level, and they're using technology and wearables to help monitor their health so that they can make adjustments to stay at peak level for as long as possible." 

The aim is to provide a complete, holistic package of care, which Easton acknowledges will pose some challenges to the pharmaceutical sector. "Our model is not necessarily that of a total care package. It's drug therapy or device and technology support therapy. So some things will need to evolve, and that's part of what my role is about." 

One way of effecting this change is by collaborating with other organisations, not necessarily limited to healthcare and life sciences. "I'm a big advocate of partnerships and joint ventures. For the pharma sector, these are traditionally through universities and research houses, but I think we need to be willing to look outside the box and look for scalable and transferable technology that is used in everyday life." 

"An example is the smartphone you probably have sitting on your desk or the smartwatch you're wearing.  These are gathering data all the time. There are probably hundreds of data points that we could use, just from our everyday technology", Easton adds. 

While apps like Apple Health, Google Health, and devices like Fitbit collect data, they could be linked to WhatsApp, WeChat or Telegraph to connect to members of a user's care team if a health issue arises. "It's using technology that is already embedded in our lives, that would enable us to share information and photographs. For example, if your knee is swelling and you want to ask a doctor for their opinion, you can send an image, then share the log from your treatment, and it becomes a way of integrating and sharing information." 

Shifting towards preventative medicine is one of Takeda's strategic goals for the next few years. An example of how this could work is how people affected by Von Willebrand disease could be supported. This lifelong bleeding disorder prevents blood from clotting and particularly affects girls and women, causing menstrual bleeding to be excessively long and heavy, which has a big impact on their quality of life. 

"It's a hereditary disorder, so many women in a family can be affected, but it's hard to diagnose", Easton explains. However, using existing technology that tracks the menstrual cycle via a smartphone perhaps an alert can be issued to let the user know when it's time to start taking replacement therapy for Von Willebrand. 

"This means that by the time a period begins, Von Willebrand levels are normalised, and menstrual flow goes down to normal levels. That's actually a massive outcome for someone who has been living with two-week-long periods that bleed through clothing every month. Suddenly for just four or five days, they can use regular tampons and pads. That's a huge improvement to life." 

The field of rare blood disorders typically hasn't seen the same amount of attention focused on it - at least in terms of tech innovation - as other chronic illnesses like diabetes. "Rare blood disorders are difficult to show returns on because you've got small patient numbers and often high costs. But if we think about the total patient journey, we could use technology to triage vast numbers of patients and data into more specific diagnosis boxes, so that what is then presented to physicians are smaller groups, of the more likely issues."

Data analysis could, for instance, show that the combination of headaches, nausea and lethargy equates to a specific type of bleeding disorder.  "You can start to put these things in categories", Easton says. "And then you're able to do differential diagnosis. But ultimately, what you're trying to do is get a faster, more accurate diagnosis, leading to a specific therapy." 

This would be more efficient than administering plasma-based treatments, for example. "A lot of bleeding disorders are caused by a deficiency of something", Easton explains. "There is a lot of combination therapy in blood disorders when you give people plasma-based products because plasma is like the golden chalice of medicine. It has a bit of everything you need. In some cases, when you don't know what the disorder is, this can help patients, but it's not the most precise way of doing it."

"That's one of the ways having very clear diagnostic support linked to advanced direct therapy can help, only treating what you need to. From a payer's perspective, it's very targeted, and there's no wasting money and resources on patients being hospitalised for things that are not necessary."

"If you go back 15-20 years, market access to the pharmaceutical industry was the emerging trend", Easton adds. "We saw all these diagrams of physician decision-making coming down and payer decision-making going up. Now we have another divergence of change, which is the application of technology to support personalised care.  This is one of the transformative pieces of pharma right now, and there are a lot of good companies, big and small, being very intelligent about how they're approaching it and investing in those spaces. There's definitely a community building." 

Share article